PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
8.60
Current Ratio 1.25–1.5x AXSM's 7.82. Bruce Berkowitz might see stronger short-term risk mitigation vs. competitor.
8.60
Quick Ratio 1.25–1.5x AXSM's 7.82. Bruce Berkowitz sees this as a distinct advantage in times of tight credit.
8.22
Similar ratio to AXSM's 7.59. Walter Schloss would see both following standard liquidity practices.
-4110.44
Both companies show negative interest coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
-69.46
Negative short-term coverage while AXSM shows 0.00. Joel Greenblatt would look for cash flow improvements and refinancing catalysts.